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Leptin and Coronary Heart Disease
Prospective Study and Systematic Review
Naveed Sattar, FRCPATH,* Goya Wannamethee, PHD,† Nadeem Sarwar, MRPHARMS, MPHIL,‡
Julia Chernova, MSC,§ Debbie A. Lawlor, MB, CHB, PHD, Anne Kelly, PHD,*
A. Michael Wallace, PHD,* John Danesh, DPHIL, FRCP,‡ Peter H. Whincup, FRCP¶
Glasgow, Scotland; and London, Cambridge, Leicester, and Bristol, England
Objectives This study sought to better determine the link between leptin and coronary heart disease (CHD).
Background Circulating leptin is considered a risk factor for CHD but larger studies are needed.
Methods Leptin levels were measured in 550 men with fatal CHD or nonfatal myocardial infarction and in 1,184 controls
nested within a prospective study of 5,661 British men and set in context with a meta-analysis.
Results Baseline leptin correlated with body mass index (BMI), blood pressure, total cholesterol, triglyceride, and inflam-
matory markers; correlations persisted after BMI adjustment. The within-person consistency of leptin values over
4 years (correlation coefficient: 0.79; 95% confidence interval [CI]: 0.73 to 0.83) was higher than those of some
established cardiovascular risk factors. In a comparison of individuals in the top third with those in the bottom
third of baseline leptin, the age- and town-adjusted odds ratio for CHD was 1.25 (95% CI: 0.96 to 1.62), decreas-
ing to 0.98 (95% CI: 0.72 to 1.34) after adjustment for BMI. A systematic review identified 7 prospective reports
with heterogeneous findings (I2  60%, 13% to 82%). The combined adjusted risk ratio across all studies was
1.44 (95% CI: 0.95 to 2.16) in a comparison of extreme thirds of leptin levels. The inconsistency between stud-
ies was partially explained by sample size, with combined estimates from studies involving 100 CHD cases
(1.28, 95% CI: 0.80 to 2.04) being somewhat weaker than those from smaller studies (1.81, 95% CI: 0.76 to
4.31).
Conclusions Previous studies appear to have overestimated associations of leptin and CHD risk. Our results suggest a moder-
ate association that is largely dependent on BMI. (J Am Coll Cardiol 2009;53:167–75) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.035l
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chere has been considerable interest in the potential rele-
ance of leptin to human metabolism and disease following
he discovery that the adipocyte ob gene in mice encodes this
ecreted protein to help regulate body weight (1). Human
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008, accepted September 23, 2008.eptin concentrations increase in obesity and correlate
trongly with percentage body fat in both men and women
2), encouraging suggestions that leptin levels are adiposity
ignals for the long-term regulation of body weight by the
rain. The possibility that leptin levels might also be
elevant to vascular disease has been raised by animal
xperiments suggesting that leptin promotes atherosclerosis
nd thrombosis in apolipoprotein E-deficient mice (3) and
y clinical studies reporting correlations of leptin levels with
stablished vascular risk factors (such as lipid concentrations
nd blood pressure) (4–7), or with markers of impaired
brinolysis (8), vascular dysfunction (9), and inflammation
10–12).
Prospective data on circulating leptin levels and incident
oronary heart disease (CHD) risk are, however, sparse. By
id-2007, 7 prospective studies (13–19) had reported on
his association. The largest such study, the WOSCOPS
West of Scotland Coronary Prevention Study) nested
ase-control study of 377 male cases and 783 controls,
eported about a 20% increase in CHD per 1 standard
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Leptin and CHD January 13, 2009:167–75deviation increase in leptin levels
after adjustment for several es-
tablished cardiovascular risk fac-
tors (15). We measured circulat-
ing leptin concentrations in
stored serum samples of 550 men
who suffered nonfatal myocardial
nfarction or coronary death and 1,184 controls who re-
ained disease free during a mean of 16 years of follow-up
n the prospective BRHS (British Regional Heart Study) of
,661 men ages 40 to 59 years from 18 British towns. In
ddition to its larger number of incident CHD cases than
n previous reports, the present study also recorded paired
eptin measurements made 4 years apart in 219 men,
nabling quantification of the within-person fluctuations
n leptin values. To help place our new data in context,
e conducted a systematic review and meta-analysis of
revious prospective reports of leptin and CHD (13–19),
nvolving a total of 1,335 CHD cases and 3,407 controls.
ethods
articipants. From 1978 to 1980, 7,735 men were ran-
omly selected from general practices in each of 24 British
owns and invited to take part in the BRHS (response rate:
8%). Nurses administered questionnaires, made physical
easurements, recorded an electrocardiograph, and in 5,661
en in 18 of the towns, collected nonfasting venous blood
amples from which serum was stored at 20°C for subse-
uent analyses. Evidence of coronary disease at entry to the
tudy was defined by the presence of either recall of any
octor diagnosis of CHD and/or electrocardiographic evi-
ence of possible or definite myocardial infarction or isch-
mia. All men were followed up for all cause mortality and
ardiovascular morbidity, and follow-up has been achieved
or 99% of the cohort (20). A “nested” case-control study
as established within the cohort. Eligible cases were 279
en who died from CHD and 364 men who had nonfatal
yocardial infarction before 1996 (21). Fatal cases were
scertained through National Health Service Central
egisters on the basis of a death certificate with Inter-
ational Classification of Diseases-Ninth Revision codes
10 to 414. Nonfatal myocardial infarction was based on
eports from general practitioners, supplemented with
ospital records confirming the diagnosis in accordance
ith World Health Organization criteria (22). Cases
ere frequency matched with 1,278 controls, on town of
esidence and age in 5-year bands, randomly selected
rom among men who did not record incident CHD by
996. Due to limited blood sample availability, leptin
easurements were available for 550 (86%) CHD cases
nd 1,184 controls (93%). However, the characteristics of
ases and controls with available blood samples did not
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
diseaseiffer from those without blood samples. oaboratory methods. Laboratory measurements were
ade blind to participants’ disease status, with samples from
atients and controls randomly distributed among assay
lates. Serum leptin was measured by an in-house radioim-
unoassay validated thoroughly against the commercially
vailable Linco assay (St. Charles, Missouri) (2). The
ntra-assay and interassay coefficients of variation were7%
nd 10%, respectively, over the sample concentration
ange. The detection limit of the assay was 0.5 ng/ml, which
s substantially lower than detection limits typically observed
ith commercially available assays (2). Because of fluctua-
ions of leptin levels over time, case-control comparisons of
ingle measurements made at baseline can underestimate
he magnitude of any associations with CHD risk. Hence,
eptin measurements were made in pairs of samples col-
ected at an interval of 4 years apart in 219 healthy control
ndividuals to help quantify the within-individual variation
23). Methods for the measurement of other risk factors in
he BRHS and their association with CHD risk have been
eported previously (24–26).
tatistical analyses. We pre-specified that case-control
nalysis would be based on comparison of extreme thirds of
eptin values in controls. Distributions of leptin, triglyceride,
-reactive protein, fibrin D-dimer, and adiponectin were
ighly positively skewed and geometric means of these
easures were used in descriptive analyses and natural
ogarithmic transformations in regression analyses. Hypoth-
ses of equal cases’ and controls’ means, proportions, and
istributions were examined by the t, likelihood ratio, and
ruskal-Wallis tests, respectively (Table 1). Analysis of
ovariance was used to obtain mean levels of continuous
stablished risk factors by thirds of leptin distribution in
ontrols, adjusted for age and then age and body mass
ndex (BMI) (Table 2); for dichotomous variables, logis-
ic regression was used to provide tests for trend across
he 3 leptin groups adjusted for age and BMI. Uncondi-
ional logistic regression models were used to calculate
dds ratios for the association of leptin with CHD, with
rogressive adjustment for possible confounding factors
Table 3). Smoking status was grouped into 4 categories:
ever smoked, ex-smokers, 20 cigarettes/day, and 20
igarettes/day; physical activity into 3 categories; alcohol
ntake into 6 categories: never drank or monthly/special,
eekends 1 to 2 drinks, weekends 3 to 6 drinks, weekends
 drinks, daily 1 to 2 drinks, daily 3 to 6 drinks, and
aily 6 drinks; and social class into 3 categories:
anual, nonmanual, and special forces; age, BMI, and
lood measurements were fitted as continuous values if not
tated otherwise. Finally, “town” was fitted as a categorical
ariable in the fixed-effect model.
A systematic review of studies published before May
007 with over 1 year’s follow-up was conducted using
earch, abstraction, and data synthesis methods previ-
usly described (27) using (where possible) nonfatal
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January 13, 2009:167–75 Leptin and CHDyocardial infarction or CHD death as end points.
orresponding investigators of all identified studies were
ontacted to provide supplementary tabular data (6 of the
contacted investigators responded). Analyses involved
nly within-study comparisons to limit possible biases.
ummary risk ratios were calculated using a random
ffects model. Heterogeneity was assessed by standard
hi-square tests and the I2 statistic, with its 95% confi-
ence interval (CI), which describes the percentage of
ariation in the logarithmic odds ratios that is attribut-
ble to genuine differences across studies rather than
andom error (28). Evidence of publication bias was
ssessed using the Egger test and by comparing pooled
esults from studies involving at least 100 CHD cases
ith those from smaller studies. Odds ratios are given
ith 95% CIs, and 2-sided probability values are used.
ll analyses were performed using Stata Statistical Soft-
are, Release 10 (StataCorp LP, College Station, Texas).
esults
ssociations of leptin levels with baseline characteristics.
s expected, established cardiovascular risk factors showed
ighly statistically significant differences between cases and
ontrols (Table 1) (24,29,30). Leptin levels were slightly
Baseline Characteristics of Participants in BRH
Table 1 Baseline Characteristics of Particip
Characteristic
Questionnaire-based
Age, yrs
Current cigarette smoker, n (%)
Evidence of coronary disease at baseline, n (%)
History of diabetes at baseline,* n (%)
Regular daily consumption of alcoholic drinks,† n (%)
Nonactive, n (%)
Nonmanual occupation, n (%)
Biophysical
Body mass index, kg/m2
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Blood-based
Total cholesterol, mmol/l
HDL cholesterol, mmol/l
Triglyceride,‡ mmol/l
C-reactive protein,‡ mg/l
White cell count, 109 cells/l
Albumin, g/l
Fibrin D-dimer,‡ ng/ml
tPA, ng/ml
von Willebrand factor, IU/dl
Adiponectin,‡ ng/ml
Leptin,‡ ng/ml
Data are presented as mean (SD) unless otherwise stated. *Based on s
drinks per day. ‡Geometric mean (interquartile range).
BRHS  British Regional Heart Study; CHD  coronary heart diseasigher in cases than in controls, but the difference was of corderline statistical significance (p  0.067). Among
ontrols, there were statistically significant positive associa-
ions of leptin levels with BMI, total cholesterol, systolic
nd diastolic blood pressure, triglyceride and several inflam-
atory markers, and inverse associations with smoking,
fter adjustment for age alone (Table 2). Leptin levels were
ot associated with alcohol intake or baseline history of
HD or diabetes. Further adjustment for BMI attenuated
ssociations of leptin levels with systolic blood pressure and
igh-density lipoprotein cholesterol, but associations with
moking, social class, total cholesterol, triglyceride, diastolic
lood pressure, and C-reactive protein remained highly
tatistically significant. Among inflammatory markers,
eptin levels were positively associated with levels of
-reactive protein, serum amyloid A, albumin, tissue-
lasminogen activator antigen, and von Willebrand fac-
or; no appreciable adjusted associations were observed
ith white cell count, D-dimer, or adiponectin levels.
urther adjustment for smoking did not materially alter
hese cross-sectional associations (data available upon
equest).
ithin-person variation in leptin levels. In an analysis of
aired leptin measurements made in 219 participants ap-
roximately 4 years apart, the within-person correlation
in BRHS
Cases (n  550) Controls (n  1,184) p Value
2.6 (5.2) 52.5 (5.3) Matched
85 (52.0%) 502 (42.5%) 0.001
80 (32.8%) 205 (17.4%) 0.001
15 (2.7%) 19 (1.6%) 0.124
06 (19.2%) 268 (22.8%) 0.090
13 (67.0%) 637 (60.8%) 0.021
90 (34.6%) 475 (40.0%) 0.031
5.9 (3.4) 25.4 (3.3) 0.001
1.9 (22.0) 146.7 (21.1) 0.001
5.7 (13.6) 82.8 (13.3) 0.001
6.6 (1.05) 6.2 (0.99) 0.001
.09 (0.27) 1.15 (0.27) 0.001
.94 (1.37–2.78) 1.68 (1.14–2.42) 0.001
2.4 (1.2–5.3) 1.4 (0.5–3.4) 0.001
7.6 (1.8) 7.2 (1.8) 0.001
4.4 (2.6) 44.5 (2.5) 0.486
92 (49–145) 77 (42–121) 0.001
3.1 (6.0) 11.5 (5.6) 0.001
8.0 (41.6) 112.4 (43.5) 0.011
0.2 (7.3–13.9) 10.3 (7.3–14.9) 0.626
4.7 (3.1–8.8) 4.3 (2.6–8.3) 0.067
rt. †Regular daily consumption of alcoholic drinks was defined as2
 high-density lipoprotein; tPA  tissue plasminogen activator.S
ants
CHD
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Leptin and CHD January 13, 2009:167–75igher than corresponding coefficients observed in these
en over the same interval for levels of total cholesterol
0.71; 95% CI: 0.58 to 0.81) and systolic blood pressure
0.59; 95% CI: 0.48 to 0.70) (31).
eptin levels and CHD risk. In a comparison of men in
he top third of measured baseline control leptin values with
hose in the bottom third, the age and town adjusted odds
atio of CHD was 1.25 (95% CI: 0.96 to 1.62) (Table 3).
urther adjustment for BMI attenuated the odds ratio to
aseline Characteristics Among Controls Across Thirds of Leptin L
Table 2 Baseline Characteristics Among Controls Across Third
Bottom Third
(n  395)
Middle
(n 
Leptin range, ng/ml 3.24 3.24
Questionnaire-based
Age, yrs 52.3 (0.3) 52.2 (
Current cigarette smoker, n (%) 213 (53.9%) 158 (
Evidence of coronary disease at baseline, n (%) 69 (17.5%) 62 (
History of diabetes at baseline, n (%) 4 (1.0%) 11 (
Consumption of 2 alcoholic drinks/day, n (%) 83 (21.0%) 88 (
Nonmanual occupation, n (%) 101 (25.6%) 167 (
Nonactive, n (%) 237 (31.3%) 247 (
Biophysical
Body mass index, kg/m2 23.1 (0.1) 25.4 (
Systolic blood pressure, mm Hg 143.1 (1.0) 145.5 (
Diastolic blood pressure, mm Hg 77.8 (0.6) 83.1 (
Blood-based
Total cholesterol, mmol/l 5.87 (0.05) 6.27 (
HDL cholesterol, mmol/l 1.20 (0.01) 1.14 (
Loge triglyceride, mmol/l 0.29 (0.03) 0.57 (
Loge C-reactive protein, mg/l 0.03 (0.07) 0.35 (
Loge serum amyloid A, mg/l 1.78 (0.8) 1.96 (
White cell count, 109 cells/l 7.3 (1.9) 7.1 (
Albumin, g/l 44.1 (2.5) 44.6 (
Loge fibrin D-dimer, ng/ml 4.37 (0.86) 4.31 (
tPA, ng/ml 9.1 (4.8) 11.3 (
von Willebrand factor, IU/dl 108.8 (42.1) 109.9 (
Loge adiponectin, ng/ml 2.39 (0.52) 2.32 (
ata are presented as mean (SD) unless otherwise stated.
BMI  body mass index; NA  not available; other abbreviations as in Table 1.
elative Odds of CHD Among Participants Who Had Leptin Levels iistribution of Values for Controls Versus Those Who Had Valu s in
Table 3 Relative Odds of CHD Among Participants Who Had LeDistribution of Values for Controls Versus Those Who H
CHD Cases
Top
Third
Middle
Third
Bottom
Third
Top
Third
M
All men‡ 188 211 151 393
Excluding men with evidence of
prevalent CHD at baseline
114 142 112 317
Excluding men with evidence of
prevalent diabetes at baseline
181 208 146 389
Cut points for bottom and top thirds leptin were 3.24 and 7.03 ng/ml, respectively. †Other pote
ressure, alcohol consumption, physical activity, and social class. ‡The adjusted odds ratios for CH
I: 0.86 to 1.62) for the top third as compared with the middle third of the distribution, and 0.98 (95% C
CI  confidence interval; other abbreviations as in Table 1..98 (95% CI: 0.72 to 1.34), and after additional adjustment
or other established cardiovascular risk factors the odds
atio was 0.95 (95% CI: 0.65 to 1.37). When fitted as a
inear continuous variable, the logarithm of leptin levels was
ot significantly associated with CHD risk, even in the age-
nd town-adjusted model (p  0.112). Exclusion of men
ith pre-existing CHD or diabetes made no material
ifference to the findings (Table 3), and there was no
mportant difference in the magnitude of the association in
eptin Levels
Top Third
(n  393)
p Value for Trend
(Adjusted for Age)
p Value for Trend
(Further Adjusted for BMI)
7.03
53.0 (0.3) 0.061 0.150
) 131 (33.3%) 0.001 0.001
) 74 (18.9%) 0.882 0.216
4 (1.1%) 0.957 0.378
) 97 (24.6%) 0.174 0.530
) 175 (44.4%) 0.001 0.001
273 (36.1%) 0.012 0.004
27.7 (0.1) 0.001 NA
151.5 (1.0) 0.001 0.312
87.6 (0.6) 0.001 0.001
6.43 (0.05) 0.001 0.001
1.12 (0.01) 0.001 0.557
0.70 (0.03) 0.001 0.001
0.67 (0.07) 0.001 0.003
2.07 (0.56) 0.001 0.002
7.2 (1.7) 0.584 0.516
44.8 (2.4) 0.001 0.009
4.35 (0.90) 0.616 0.615
14.3 (6.0) 0.001 0.001
118.5 (45.1) 0.001 0.001
2.28 (0.54) 0.001 0.236
Top Third of theB ttom Third of the Same Distribution*
Levels in the Top Third of the
alues in the Bottom Third of the Same Distribution*
ls
Odds Ratio (95% CI)
p Value for Trend Across Thirds
Bottom
Third
Adjusted for Age
and Town
Adjusted for Age,
Town, and BMI
Adjusted for Age,
Town, BMI, and
Other Potential
Confounders†
393 1.25 (0.96–1.62)
0.11
0.98 (0.72–1.34)
0.85
0.95 (0.65–1.37)
0.73
326 1.04 (0.76–1.42)
0.80
0.91 (0.63–1.32)
0.61
0.79 (0.51–1.23)
0.29
390 1.24 (0.95–1.62)
0.13
0.94 (0.69–1.30)
0.65
0.93 (0.64–1.36)
0.65
nfounders included total cholesterol, HDL cholesterol, triglyceride, smoking status, systolic blood
British Regional Heart Study with the use of alternative comparisons were as follows: 1.18 (95%evels
s of L
Third
396)
–7.03
0.3)
40.0%
15.7%
2.8%)
22.3%
42.3%
32.6)
0.1)
1.0)
0.6)
0.05)
0.01)
0.03)
0.07)
0.67)
1.7)
2.5)
0.91)
4.7)
42.8)
0.56)n thethe
ptin
ad V
Contro
iddle
Third
396
333
385
ntial co
D in theI: 0.92 to 1.03) for a 50% increase in baseline leptin levels.
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January 13, 2009:167–75 Leptin and CHDmokers and nonsmokers (p 0.14 in a test for interaction).
esults were similar in analyses of extreme fifths of leptin
evels.
ystematic review and meta-analysis of available pro-
pective studies. We identified 8 relevant published pro-
pective studies (including the current study) that reported
n circulating leptin levels and CHD risk (Fig. 1), involving
total of 1,335 cases and 3,407 controls (weighted mean age
t entry: 55 years; weighted mean follow-up: 10 years)
Table 4). One study did not report risk estimates for CHD
hat had been adjusted for age and sex only. There was
vidence of substantial heterogeneity among these studies of
isk estimates adjusted for age and sex only (chi-square test
ith 6 degrees of freedom for heterogeneity  30.38, p 
.001; I2  80% [60% to 90%]), and of risk estimates
urther adjusted for established cardiovascular risk factors
chi-square test with 7 degrees of freedom  17.52, p 
.014; I2 60% [13% to 82%]). In a comparison of extreme
hirds of leptin levels, the combined risk ratio across all
tudies was 2.28 (95% CI: 1.42 to 3.68) in analyses adjusted
or age and sex only, and it was 1.44 (95% CI: 0.95 to 2.16)
79 potentially relevant reports 
identified
38 reports retrieved for evaluation of 
abstracts
33 full-text articles retrieved for more 
detailed evaluation
7 studies included in the current 
review
Figure 1 Quality of Reporting of Meta-Analyses Flow Diagram
The diagram summarizes the search strategy used to identify prospective studiesn analyses further adjusted (Fig. 2). Although formal ttatistical tests did not detect strong evidence of significant
ublication bias (Egger test: p  0.15), studies involving at
east 100 CHD cases yielded weaker risk ratios compared
ith smaller studies (1.62 [95% CI: 1.17 to 2.24] vs. 3.55
95% CI: 1.08 to 11.74] for analyses adjusted for age and sex
nly; 1.28 [95% CI: 0.80 to 2.04] vs. 1.81 [95% CI: 0.76 to
.31] for analyses further adjusted), which might reflect
referential publication of striking findings from smaller
tudies.
iscussion
he present report is the largest single study thus far on
eptin levels and incident CHD. It found a moderate and
tatistically nonsignificant association between leptin levels
nd CHD risk that attenuated to the null following adjust-
ent for BMI. But, even after adjustment for measured
MI values, leptin levels remained significantly associated
ith baseline values of smoking, lipids, blood pressure, and
everal circulating markers of inflammation. In addition,
his study found a high degree of within-individual consis-
eports excluded after screening of titles:
=41
eports excluded after screening of abstracts:
animal based studies (n=1) 
studies not assessing cardiovascular       
utcomes (n=3) 
review articles (n=1)
eports excluded after reading of full texts:
cross sectional correlation studies (n=12) 
retrospective case-control studies (n=11) 
studies not assessing CHD outcomes (n=3)
ulating lipid levels and coronary heart disease (CHD) outcomes.R
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Leptin and CHD January 13, 2009:167–75han the corresponding values in the same participants for
stablished cardiovascular risk factors such as total choles-
erol and systolic blood pressure.
On the basis of the present study and systematic review,
t is likely that the strength of any independent association
f leptin levels with CHD is, at most, moderate. Given the
trong relationship between leptin, body weight and BMI,
his would be consistent with the moderate strength of
ssociation between BMI and CHD risk in middle age. In
he present study, the age-adjusted relative risk of CHD in
he top third of the control BMI distribution was 1.35 (95%
I: 1.06 to 1.71) compared with the lowest third, with an
ncrease in CHD risk of 5% (95% CI: 2% to 8%) for each
ilogram per square meter increase in BMI. The moderate
trength of this association is consistent with that observed
n other prospective studies (32).
Obese individuals are characterized by hyperleptinemia
nd potentially leptin “resistance.” There is extensive basic
xperimental evidence linking elevations in leptin, or loss of
eptin function via resistance, to atherogenesis and CHD
33–36). For example, it has been suggested that normally
unctioning leptin, via its effects to up-regulate fatty acid
eta-oxidation, helps to prevent toxic lipid accumulation in
ritical organs so that the peripheral resistance is the critical
athogenic feature, rather than leptin excess itself (36).
qually complex is the potential interaction between
eptin and the endothelium. For example, although
levated leptin levels have been associated with poor
ascular compliance in adolescents (9) and impaired
oronary vasoreactivity in otherwise healthy young obese
ndividuals (37), evidence from cellular work suggests that
eptin may have both vasoconstrictor and vasodilator effects
hrough the endothelium-dependent mechanism (38). Lep-
in induces vasoconstriction via the potent vasoconstrictor,
ndothelin-1, but can also promote vasodilation via release
f nitric oxide (39). It is conceivable that, in parallel with
nsulin-mediated vascular effects, leptin-induced vasodi-
ation is blunted in obese subjects by other pathways (e.g.,
erivascular adipocyte release of cytokines) (40), also
inked to obesity, enabling its vasoconstrictor actions to
ominate.
The strengths and potential limitations of the present
tudy merit careful consideration. The present study almost
oubles the number of incident CHD cases studied in
elation to leptin levels. Data were derived from analyses in
he BRHS, a population-based prospective study with high
esponse and follow-up rates and robust ascertainment of
ncident major CHD outcomes (20,21). As many estab-
ished cardiovascular risk factors, emerging markers, and
ther characteristics were recorded at baseline in the BRHS,
his information has enabled a detailed assessment of the
aseline correlates of leptin levels and careful adjustment for
otential confounding factors. Data from paired measure-
ents in 219 participants in this study provide the most
eliable evidence thus far on the long-term variability of
leptin levels, suggesting that leptin is a comparatively stableCh T S
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January 13, 2009:167–75 Leptin and CHDirculating marker. As the BRHS has previously demon-
trated the expected associations of CHD incidence with
everal established cardiovascular risk factors (24,25), it is an
nformative study with which to put into perspective the
eaker association observed between leptin levels and CHD
isk. Our systematic review of previous prospective studies
f leptin levels and CHD highlights the strengths of the
resent report and helps to put the present data into context.
espite attempts to improve comparability between studies
y contacting principal investigators to provide results in a
onsistent manner, there was considerable heterogeneity
mong the available prospective studies, which warrants
urther investigation. Nevertheless, available data suggest a
ore modest association of leptin with CHD than previ-
usly suspected, with any association largely dependent
pon BMI.
Our primary study was conducted solely in men and
he majority of previously published prospective studies
ere also either solely in men or contained a majority of
en (Table 4). Only 1 previous study (BWHHS [British
omen’s Heart and Health Study]) was conducted solely
n women and this study demonstrates that women have
ubstantially higher circulating leptin levels than men
A          Adjusted for age and seStudy No. of CHD cases
0.5 1.0 2.0 4.0
550
377
86†
62
55
171
19
15
BRHS
WOSCOPS
Quebec
Northern Sweden
BWHHS
CAPPP
Mayo
Zocalli et al.
Studies based in essentially general populations
Studies based in populations with pre-existing disease
Risk ratio (95% CI): top third vs. bottom
N / R
Figure 2 Prospective Studies of Circulating Leptin Levels and C
There was evidence of substantial heterogeneity among the studies presented in p
0.001; I2  80% [60% to 90%]), and plot (B) (chi-square test with 7 degrees of fr
all studies was 2.28 (95% confidence interval [CI]: 1.42 to 3.68) in analyses adju
adjusted for established risk factors. Studies involving at least 100 CHD cases yie
vs. 3.55 [95% CI: 1.08 to 11.74] for analyses adjusted for age and sex only; 1.28
adjusted). Risk ratios for CHD in a comparison of extreme thirds of leptin levels ar
box sizes are proportional to the inverse of the variance. *All studies adjusted for
except the Quebec Cardiovascular Study, which did not adjust for lipids. †Included
Study; BWHHS  British Women’s Heart Health Study; CAPPP  Captopril Prevent
Scotland Coronary Outcomes Prevention Study.Table 4). Although we recently reported no statistically significant association of leptin levels with CHD risk
including fatal CHD, acute myocardial infarction, re-
ascularization, and new angina) in 165 cases and 355
ontrols in BWHHS (19) (results in Table 4 are for the
5 cases with fatal CHD or acute myocardial infarction),
uch larger studies are needed to assess any gender-
pecific associations. Further studies are also needed in
ifferent ethnic populations (41,42). Although serum
amples in the present study were stored at 20°C for
any years, leptin does not appear to be appreciably
nfluenced by delayed measurement, prolonged storage,
r by repeated freeze-thaw cycles (43). Moreover, our
emonstration of high levels of leptin reproducibility
alidates the sample storage and assay methods used in
he present study, as do the observations that mean leptin
evels in the present study were very similar to those
reviously reported in a prospective study of middle-aged
ritish men involving the same laboratory personnel and
sing the same assay as in the current study (15). As
eptin levels in the present study were, as expected,
orrelated with BMI, certain other established cardiovas-
ular risk factors, and markers of inflammation, these
ndings further reinforce the validity of the present
B       Further adjusted for established 
cardiovascular risk factors*
16 0.5 1.0 2.0 4.0 8.0 16
Risk ratio (95% CI): top third vs. bottom third
) (chi-square test with 6 degrees of freedom for heterogeneity  30.38, p 
 17.52, p  0.014; I2  60% [13% to 82%]). The combined risk ratio across
r age and sex only, and 1.44 (95% CI: 0.95 to 2.16) in analyses further
eaker risk ratios compared with smaller studies (1.62 [95% CI: 1.17 to 2.24]
CI: 0.80 to 2.04] vs. 1.81 [95% CI: 0.76 to 4.31] for analyses further
ented for each study. Horizontal lines represent 95% confidence intervals and
imum of smoking status, lipids, systolic blood pressure, and body mass index,
duals with angina and coronary insufficiency. BRHS  British Regional Heart
oject; CHD  coronary heart disease; N/R  not reported; WOSCOPS  West ofx only
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revious studies may have overestimated associations of
eptin and CHD risk, as available data indicate the existence
f comparatively moderate associations that are largely
ependent on BMI.
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